Dae Hyun Kim1, Francine Grodstein2, Anne B Newman3, Paulo H M Chaves4, Michelle C Odden5, Ronald Klein6, Mark J Sarnak7, Kushang V Patel8, Lewis A Lipsitz9. 1. Division of Gerontology, Beth Israel Deaconess Medical Center, Institute for Aging Research, Hebrew SeniorLife, and dkim2@bidmc.harvard.edu. 2. Channing Division of Network Medicine, Brigham and Women's Hospital, Boston, Massachusetts. 3. Department of Epidemiology, University of Pittsburgh, Pennsylvania. 4. Benjamin Leon Center for Geriatric Research and Education, Herbert Wertheim College of Medicine, Florida International University, Miami. 5. School of Biological and Population Health Sciences, Oregon State University, Corvallis. 6. Department of Ophthalmology and Visual Sciences, University of Wisconsin School of Medicine and Public Health, Madison. 7. Division of Nephrology, Tufts Medical Center, Boston, Massachusetts. 8. Department of Anesthesiology and Pain Medicine, University of Washington, Seattle. 9. Division of Gerontology, Beth Israel Deaconess Medical Center, Institute for Aging Research, Hebrew SeniorLife, and.
Abstract
BACKGROUND: Microvascular and macrovascular abnormalities are frequently found on noninvasive tests performed in older adults. Their prognostic implications on disability and life expectancy have not been collectively assessed. METHODS: This prospective study included 2,452 adults (mean age: 79.5 years) with available measures of microvascular (brain, retina, kidney) and macrovascular abnormalities (brain, carotid, coronary, peripheral artery) in the Cardiovascular Health Study. The burden of microvascular and macrovascular abnormalities was examined in relation to total, activity-of-daily-living disability-free, and severe disability-free life expectancies in the next 10 years (1999-2009). RESULTS: At 75 years, individuals with low burden of both abnormalities lived, on average, 8.71 years (95% confidence interval: 8.29, 9.12) of which 7.67 years (7.16, 8.17) were without disability. In comparison, individuals with high burden of both abnormalities had shortest total life expectancy (6.95 years [6.52, 7.37]; p < .001) and disability-free life expectancy (5.60 years [5.10, 6.11]; p < .001). Although total life expectancy was similarly reduced for those with high burden of either type of abnormalities (microvascular: 7.96 years [7.50, 8.42] vs macrovascular: 8.25 years [7.80, 8.70]; p = .10), microvascular abnormalities seemed to have larger impact than macrovascular abnormalities on disability-free life expectancy (6.45 years [5.90, 6.99] vs 6.96 years [6.43, 7.48]; p = .016). These results were consistent for severe disability-free life expectancy and in individuals without clinical cardiovascular disease. CONCLUSIONS: Considering both microvascular and macrovascular abnormalities from multiple noninvasive tests may provide additional prognostic information on how older adults spend their remaining life. Optimal clinical use of this information remains to be determined.
BACKGROUND: Microvascular and macrovascular abnormalities are frequently found on noninvasive tests performed in older adults. Their prognostic implications on disability and life expectancy have not been collectively assessed. METHODS: This prospective study included 2,452 adults (mean age: 79.5 years) with available measures of microvascular (brain, retina, kidney) and macrovascular abnormalities (brain, carotid, coronary, peripheral artery) in the Cardiovascular Health Study. The burden of microvascular and macrovascular abnormalities was examined in relation to total, activity-of-daily-living disability-free, and severe disability-free life expectancies in the next 10 years (1999-2009). RESULTS: At 75 years, individuals with low burden of both abnormalities lived, on average, 8.71 years (95% confidence interval: 8.29, 9.12) of which 7.67 years (7.16, 8.17) were without disability. In comparison, individuals with high burden of both abnormalities had shortest total life expectancy (6.95 years [6.52, 7.37]; p < .001) and disability-free life expectancy (5.60 years [5.10, 6.11]; p < .001). Although total life expectancy was similarly reduced for those with high burden of either type of abnormalities (microvascular: 7.96 years [7.50, 8.42] vs macrovascular: 8.25 years [7.80, 8.70]; p = .10), microvascular abnormalities seemed to have larger impact than macrovascular abnormalities on disability-free life expectancy (6.45 years [5.90, 6.99] vs 6.96 years [6.43, 7.48]; p = .016). These results were consistent for severe disability-free life expectancy and in individuals without clinical cardiovascular disease. CONCLUSIONS: Considering both microvascular and macrovascular abnormalities from multiple noninvasive tests may provide additional prognostic information on how older adults spend their remaining life. Optimal clinical use of this information remains to be determined.
Authors: Caterina Rosano; Lewis H Kuller; Hyoju Chung; Alice M Arnold; William T Longstreth; Anne B Newman Journal: J Am Geriatr Soc Date: 2005-04 Impact factor: 5.562
Authors: L P Fried; N O Borhani; P Enright; C D Furberg; J M Gardin; R A Kronmal; L H Kuller; T A Manolio; M B Mittelmark; A Newman Journal: Ann Epidemiol Date: 1991-02 Impact factor: 3.797
Authors: A R Sharrett; L D Hubbard; L S Cooper; P D Sorlie; R J Brothers; F J Nieto; J L Pinsky; R Klein Journal: Am J Epidemiol Date: 1999-08-01 Impact factor: 4.897
Authors: Sarah E Vermeer; Niels D Prins; Tom den Heijer; Albert Hofman; Peter J Koudstaal; Monique M B Breteler Journal: N Engl J Med Date: 2003-03-27 Impact factor: 91.245
Authors: W T Longstreth; Alice M Arnold; Norman J Beauchamp; Teri A Manolio; David Lefkowitz; Charles Jungreis; Calvin H Hirsch; Daniel H O'Leary; Curt D Furberg Journal: Stroke Date: 2004-11-29 Impact factor: 7.914
Authors: S Vigili de Kreutzenberg; A Coracina; A Volpi; G P Fadini; A C Frigo; G Guarneri; A Tiengo; A Avogaro Journal: Nutr Metab Cardiovasc Dis Date: 2010-02-16 Impact factor: 4.222
Authors: Chelsea E Myers; Ronald Klein; Michael D Knudtson; Kristine E Lee; Ronald Gangnon; Tien Y Wong; Barbara E K Klein Journal: Ophthalmology Date: 2012-08-20 Impact factor: 12.079
Authors: Mark J Sarnak; Ronit Katz; Linda F Fried; David Siscovick; Brian Kestenbaum; Stephen Seliger; Dena Rifkin; Russell Tracy; Anne B Newman; Michael G Shlipak Journal: Arch Intern Med Date: 2008-01-28
Authors: Andrea R Zammit; Mindy J Katz; Jennifer Y Lai; Molly E Zimmerman; Markus Bitzer; Richard B Lipton Journal: J Gerontol A Biol Sci Med Sci Date: 2014-11-13 Impact factor: 6.053
Authors: Joshua A Beckman; Meredith S Duncan; Scott M Damrauer; Quinn S Wells; Joey V Barnett; David H Wasserman; Roger J Bedimo; Adeel A Butt; Vincent C Marconi; Jason J Sico; Hilary A Tindle; Marc P Bonaca; Aaron W Aday; Matthew S Freiberg Journal: Circulation Date: 2019-07-08 Impact factor: 29.690
Authors: Ferenc Deak; Willard M Freeman; Zoltan Ungvari; Anna Csiszar; William E Sonntag Journal: J Gerontol A Biol Sci Med Sci Date: 2015-11-20 Impact factor: 6.053
Authors: Lewis H Kuller; Oscar L Lopez; John S Gottdiener; Dalane W Kitzman; James T Becker; Yuefang Chang; Anne B Newman Journal: J Am Heart Assoc Date: 2017-07-22 Impact factor: 5.501
Authors: Dae Hyun Kim; Francine Grodstein; Anne B Newman; Paulo H M Chaves; Michelle C Odden; Ronald Klein; Mark J Sarnak; Lewis A Lipsitz Journal: J Am Geriatr Soc Date: 2015-09-04 Impact factor: 5.562